Cyclooxygenase-2 inhibition and gastric cancer

Current Pharmaceutical Design

Volumn 9, Issue 27, 2003, Pages 2281-2288

  Jiang, Xiao Hua ^a   Wong, Benjamin C Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Cyclooxygenase; Epidemiology; Gastric cancer; Intervention; Premalignant lesions; Prevention; Prostaglandin

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; CARCINOGEN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; IBUPROFEN; INDOMETACIN; ISOENZYME; METHYLNITRONITROSOGUANIDINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; SULINDAC; TILMACOXIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; DRUG USE; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; LONG TERM CARE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; STOMACH CANCER; TUMOR XENOGRAFT;

ANIMALS; CLINICAL TRIALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STOMACH NEOPLASMS;

EID: 0141449984     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033453983     Document Type: Review

References (108)

1. 716 knocknout mice by inhibition of prostaglandin endoperoxide synthase-2 (COX-2). Cell 1996; 87: 803-809.
2. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-412.
3. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362-366.
4. Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999; 59: 3387-3391.
5. Thun MJ, Namboodiri MN, Calle EE, Eugenia EC, Flanders WD, Health CWJr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327.
6. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willet WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 7: 333(10): 609-14.
7. Giovannucci E, Rimm EG, Stampfer MJ, Colditz GA, Asherio A, Willet WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 15: 121(4): 241-6.
8. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342(26),1946-52.
9. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996; 7(2): 203-5.
10. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5(2): 138-46.
11. Kargman SL, O'Neill GP, Vichers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 15: 55(12): 2556-9.
12. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakammura S. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 1: 58(17): 3761-4.
13. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59(5): 987-90.
14. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58(14): 2929-34.
15. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83(3): 493-501
16. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93(5): 705-16.
17. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105(11): 1589-94.
18. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94(7): 3336-40.
19. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999; 1438(1): 120-30.
20. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80.
21. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107(4): 1183-8.
22. Jiang XH, Lam SK, Lin MC, Jiang SH, Kung HF, Slosberg ED, et al. Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway Oncogene 2002; 21(39): 6113-22.
23. Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, et al. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001; 22(9): 1393-7.
24. Zhu GH, Wong BC, Solsberg ED, Eggo MC, Ching CK, Yuen ST, et al. Overexpression of protein kinase C-beta 1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology 2000; 118(3): 507-14.
25. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111(2): 445-54.
26. Soydan AS, Gaffen JD, Weech PK, Tremblay NM, Kargman S, O'Neill G, et al. Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours. Eur J Cancer 1997; 33(9): 1508-12.
27. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncology 1998; 69(3): 168-72.
28. Uefuji K, Ichikura T, Shinomiya N, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6(1): 135-8.
29. Murata H, Kawano S, Tsuji S, Tsujii M, Sawaoka H, Kimura Y. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterology 1999; 94: 451.
30. Yamamoto H, Itoh F, Fukushima H, Hinoda Y, Imai, K. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability. Int J Cancer 1999; 84: 400-3.
31. Yamagata R, Shimoyama T, Fukuda S, Yoshimura T, Tanaka M, Munakata A. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterology Hepatology 2002; 14(4): 359-63.
32. Saukkonen K, Nieminen O, van Rees B, Vikki S, Harkonen M, Juhola M, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001; 7(7): 1923-31.
33. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998; 58(23): 5473-7.
34. Lee TL, Leung WK, Lau JY, Tong JH, Ng EK, Chan FK, et al. Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer. Cancer Lett 2001; 26: 168(2): 133-40.
35. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6(2): 519-25.
36. Van Rees BP, Saukkoene K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathology 2002; 196(2): 171-9.
37. Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91(10): 1876-81.
38. Uefuji K, Ichikura T, Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncology 2001; 76(1): 26-30.
39. Asaka M. Helicobacter pylori infection and gastric cancer. Intern Med 2002; 11(1): 1-6.
40. Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 1999; 116(6): 1319-29
41. McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM, Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterology 1999; 94(5): 1218-23.
42. Sawaoka H, Kawano S, Tsujii S, Tsuji M, Sun W, Gunawan ES, et al. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins. Leukot Essent Fatty Acids 1998; 59(5): 313-6.
43. Zarrilli R, Tuccillo C, Santangelo M, Nardone G, Romano M. Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis. Am.J Gastroenterology 1999; 94(11): 3376-8.
44. Chan FK, To KF, Ng YP, Lee TL, Cheng AS, Leung WK, et al. Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis. Aliment Pharmacology Ther 2001; 15(2): 187-93.
45. To KF, Chan FK, Cheng AS, Lee TL, Ng YP, Sung JJ. Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacology Ther 2001; 15(1): 25-34.
46. Romano M, Ricci V, Memoli A, Tuccillo C, Di Popolo A, Sommi P. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biology Chem 1998; 273(44): 28560-3.
47. Ristimäki A, Narko K, Nieminen O, Saukkonen K. Role of cyclooxygenase-2 in carcinogenesis other than colorectal cancer. In: Therapeutic roles of selective COX-2 inhibitors. Vane, J.R. and Botting, R.M., Ed; William Harvey Press; London. 2001, pp 418-441.
48. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathology 2000; 157(3): 729-35.
49. Wambura C, Aoyama N, Shirasaka D, Sakai T, Ikemura T, Sakashita M, et al. Effect of Helicobacter pylori-induced cyclooxygenase-2 on gastric epithelial cell kinetics: implication for gastric carcinogenesis. Helicobacter 2002; 7(2): 129-38.
50. Konturek PC, Hartwich A, Zuchowicz M, Labza H, Pierzchalski P, Karczewska E, et al. Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer. J Physiology Pharmacology2000; 51(4 Pt 1): 737-49.
51. Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci 2001; 46(10): 2277-84.
52. Kim H, Lim JW, Kim KH. Helicobacter pylori-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: mediation by nuclear factor-kappaB. Scand J Gastroenterology 2001; 36(7): 706-16.
53. Akhta M, Cheng Y, Magno RM, Ashktorab H, Smoot DT, Meltzer SJ, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001; 61(6): 2399-403.
54. Konturek PC, Konturek SJ, Pierzchalski P, Starzynska T, Marlicz K, Hartwich A, et al. Gastric MALT-lymphoma, gastrin and cyclooxygenases. Acta Gastroenterology Belg 2002; 65(1): 17-23.
55. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biology Chem 1992; 267(7): 4338-44.
56. Kujubu DA, Herschman HRJ. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biology Chem 1992; 25: 267(12): 7991-4.
57. Seibert K, Zhang Y, Leahy K, Hauser S, Masferer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91(25): 12013-7.
58. Takahashi S, Shigeta J, Inoue H, Tanabe T, Okabe S. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiology 1998; 275(5 Pt 1): G1137-45
59. Brzozowski T, Konturek PC, Konturek SJ, Paido R, Schuppan D, Drozdowicz D, et al. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiology Pharmacology 2000; 51(4 Pt 1): 751-73.
60. Jones MK, Sasaki E, Halter F, Pai R, Nakamura T, Arakawa T, et al. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J 1999; 13(15): 2186-94.
61. Obonyo M, Guiney DG, Harwood J, Fierer J, Cole SP. Role of gamma interferon in Helicobacter pylori induction of inflammatory mediators during murine infection. Infect Immun 2002; 73(6): 3295-9.
62. Brzozowski T, Konturek PC, Konturek SJ, Schuppan D, Drozdowicz D, Kwiecien S, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. Digestion 2001; 64(1): 15-29.
63. Habib A, Creminon C, Frobert Y. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biology Chem 1993; 268(31): 23448-54.
64. O'Banion KM, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992; 89(11): 4888-92.
65. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid-and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20(3): 445-51.
66. Fan XM, Wong BC, Lin MC, Cho CH, Wang WP, Kung HF, et al. Interleukin-1beta induces cyclo-oxygenase-2 expression in gastric cancer cells by the p38 and p44/42 mitogen-activated protein kinase signaling pathways. J Gastroenterology Hepatology 2001; 16(10): 1098-104.
67. Hull MA, Thomson JL, Hawkey CJ. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 1999; 45(4): 529-36.
68. Noach LA, Bosma NB, Jansen J. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterology 1994; 29(5): 425-9.
69. Yamaoka Y, Kita M, Kodama T. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996; 110(6): 1744-52.
70. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 15: 87(6): 095-147.
71. Reddy ST, Wadleigh DJ, Herschman HRJ. Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J Biology Chem 2000; 275(5): 3107-13.
72. Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biology Chem 2000; 275(9): 6259-66.
73. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112(2): 387-97.
74. Sun WH, Tsuji S, Tsujii M, Gunawan ES, Kawai N, Kimura A, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacology Exp Ther 2000; 295: 295(2): 447-52.
75. Murasaki G, Zenser T, Vavis BB, Cohen, SM. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis 1984; 5(1): 53-5.
76. Newberne PM, Charnley G, Adams K, Cantor M, Suphakarn V, Roth D. Gastric carcinogenesis: a model for the identification of risk factors. Cancer Lett. 1987; 38(1-2): 149-63.
77. Takahashi M, Kokubo T, Furukawa F, Kurokawa Y, Hayashi Y. Effects of sodium chloride, saccharin, phenobarbital and aspirin on gastric carcinogenesis in rats after initiation with N-methyl-N′-nitro-N-nitrosoguanidine. Gann 1984; 75(6): 494-501.
78. Bespalov VG, Troian DN, Petrov AS, Aleksandrov VA. The inhibition of esophageal tumor development by the use of the nonsteroidal and steroidal anti-inflammatory preparations indomethacin and dexamethasone. Farmakology Toksikology 1989; 52(2): 67-70.
79. Tanaka T, Kojima T, Yoshimi N, Sugie S, Mori, H. Carcinogenesis 1999; 12(10): 1949.
80. Jalbert G, Castonguay A. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett 1992; 14: 66(1): 21-8.
81. Xiao F, Furuta T, Takashima M, Shirai N, Hanai H. Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice. Aliment Pharmacology Ther 2001; 15(6): 875-86.
82. Loogna P, Franzen L, Sipponen P, Domellof L. Cyclooxygenase-2 and Bcl-2 expression in the stomach mucosa of Wistar rats exposed to Helicobacter pylori, N′-methyl-N′-nitro-N-nitrosoguanidine and bile. Virchows Arch 2002; 441: 441(1): 77-84.
83. Zhu GH, Wong BC, Ching CK, Lai KC, Lam SK. Differential apoptosis by indomethacin in gastric epithelial cells through the constitutive expression of wild-type p53 and/or up-regulation of c-myc. Biochem Pharmacology 1999; 58(1): 193-200.
84. Fujiwara Y, Tarnawski A, Fujiwara K, Arakawa T, Kobayashi K. Inhibitory effects of indomethacin on growth and proliferation of gastric carcinoma cells KATO III. J Physiology Pharmacology 1993; 44(2): 147-53.
85. Nakamura A, Chiba T, Yamatani T, Yamaguchi A, Inui,T, MOrishita T, et al. Prostaglandin E2 and F2 alpha inhibit growth of human gastric carcinoma cell line KATO III with simultaneous stimulation of cyclic AMP production. Life Sci 1989; 44(1): 75-80.
86. Shimakura S, Boland CR. Eicosanoid production by the human gastric cancer cell line AGS and its relation to cell growth. Cancer Res 1992; 52: 52(7): 1744-9
87. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48(15): 4399-404.
88. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991; 83(5): 355-8
89. Muskat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1984; 74(7): 1847-54.
90. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154(4): 394-9.
91. Reeves MJ, Newcomb PA, Trentham- Dietz A, Stoner BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiology Biomarkers Prev. 1996; 5(12): 955-60.
92. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31(11): 691-6.
93. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 17: 85(4): 307-11.
94. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esopliageal and gastric cancer. Cancer Epidemiology Biomarkers Prev 1998; 7(2): 97-102.
95. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 1999; 2(4): 473-476.
96. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001; 84(7): 965-968.
97. Karateev AE, Nasonova VA, Murav Iu V. Intake of non-steroid preparation and risk of developing cancer of the upper gastrointestinal tract. Ter Arkh 2001; 73(12): 71-3.
98. Wong BCY, Jiang XH, Fan, XM, Lin MCM, Jiang SH, Lam SK, et al. Suppression of RelA/p65 nuclear translocation independent of IκB-α degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene. (in press)
99. Tsuji S, Kawano S, Sawaoka H, Takei Y, Kobayashi I, Nagano K, et al. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins. Leukot Essent Fatty Acids 1996; 55(3): 179-83.
100. Wu YL, Sun B, Zhang XJ, Wang SN, He HY, Qiao MM, et al. Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol 2001; 7(6): 796-800.
101. Husain SS, Szabo IL, Pai R, Soreghan B, Jones MK, Tarnawski AS. MAPK (ERK2) kinase--a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci 2001; 69(25-26): 3045-3054.
102. Li HL, Chen DD, Li XJ, Zhang HW, Lu JH, Ren XD, et al. JTE-522-induced apoptosis in human gastric adenocarcinoma [correction of adenocarinoma] cell line AGS cells by caspase activation accompanying cytochrome C release, membrane translocation of Bax and loss of mitochondrial membrane potential. World J Gastroenterology 2002; 8(2): 217-223.
103. Singh G. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacology Ther 1994: 62(1-2): 175-91.
104. Mestre JR. Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997; 15: 57(14): 2890-5.
105. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000; 60(7): 1864-70.
106. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Design 2002; 8(12): 1035-62.
107. Rodriguez-Tellez M, Arguelles F, Herrerias JM Jr, Ledro D, Esteban J, Herrerias JM. Antiinflamatory agents less dangerous for gastrointestinal tract. Curr Pharm Design 2001; 7(10): 951-76.
108. Simoni D, Tolomeo M. Retinoids apoptosis and cancer. Curr Pharm Design 2001; 7(17): 1823-37.